Oxandrolone monograph

Lithium and salicylate toxicity. Caution with NSAIDs. Antagonized by organic anion drugs (eg, probenecid) and indomethacin. Give oral dose 1hr before or 4-6hrs after cholestyramine. Ototoxicity with aminoglycosides (avoid) and ethacrynic acid. Potentiated by concomitant CYP2C9 inhibitors (eg, amiodarone, fluconazole, miconazole, oxandrolone); monitor and adjust dose if needed. Antagonized by concomitant CYP2C9 inducers (eg, rifampin); monitor and adjust dose if needed. Concomitant CYP2C9 substrates and substrates with narrow therapeutic range (eg, celecoxib, warfarin, phenytoin); monitor and adjust dose if needed. Risk of hypotension and renal impairment with concomitant ACE inhibitors, ARBs, or nephrotoxic drugs (eg, aminoglycosides, cisplatin, NSAIDs). Increased nephrotoxicity with concomitant radiocontrast agents. Increased risk of hypokalemia with concomitant corticosteroids and ACTH.

Oxandrin is available in and 10 mg tablets. The daily adult dosage of Oxandrin is mg to 20 mg given in 2 to 4 divided doses. For children the total daily dosage of Oxandrin is less than .1 mg per kilogram body weight or less than .045 mg per pound of body weight; this drug should only be administered by specialists. Oxandrin may increase sensitivity to oral anticoagulants, and interact with oral hypoglycemic agents, adrenal steroids or ACTH. This drug should not be given during pregnancy. It is unknown if Oxandrin passes into breast milk. Oxandrin may affect milk production and it may harm a nursing infant. Breastfeeding while using Oxandrin is not recommended.

This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about oxandrolone. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using oxandrolone.

Monographs:
The Drug Enforcement Administration's Special Testing and Research Laboratory generated the following monographs using structurally confirmed reference materials. These monographs are intended to be used for the verification of acquired reference materials.  Monographs are being uploaded as they are technically reviewed and approved for publication. In addition, links to monographs authored by Forensic Drug Review are provided below . For those monographs that refer to a TLC method number, please click on the TLC Systems link for more information.

For updates on when new monographs are uploaded, follow us on Twitter. Follow @swgdrug

Oxandrolone monograph

oxandrolone monograph

Monographs:
The Drug Enforcement Administration's Special Testing and Research Laboratory generated the following monographs using structurally confirmed reference materials. These monographs are intended to be used for the verification of acquired reference materials.  Monographs are being uploaded as they are technically reviewed and approved for publication. In addition, links to monographs authored by Forensic Drug Review are provided below . For those monographs that refer to a TLC method number, please click on the TLC Systems link for more information.

For updates on when new monographs are uploaded, follow us on Twitter. Follow @swgdrug

Media:

oxandrolone monographoxandrolone monograph